Murray Stewart - Aug 9, 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Interim Chief Medical Officer, Director
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Stock symbol
XFOR
Transactions as of
Aug 9, 2023
Transactions value $
-$137,859
Form type
4
Date filed
8/11/2023, 07:26 PM
Previous filing
Jan 12, 2023
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Award $0 +270K +4048.19% $0.00 277K Aug 9, 2023 Direct F1
transaction XFOR Common Stock Sale -$138K -130K -47.03% $1.06 147K Aug 10, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock acquired upon acceleration of the vesting of a performance-based restricted stock unit grant.
F2 Represents nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.